hip and knee joint disease
Conditions
Interventions
A:TXA: before incision (20mg/kg), 3, 6, 12, 18, and 24 hours later (1g) DXM: prior to anesthesia induction (20mg)
B:TXA: before incision (60mg/kg), 3, 6, 12, 18, and 24 hours later (1g) DXM: prior to anesthesia induction (20mg)
C:TXA: before incision (60mg/kg), 3, 12, and 24 hours later (1g) DXM: prior to anesthesia induction (20mg)
D:TXA: before incision (20mg/kg), 3 hours later (2g) DXM: prior to anesthesia induction (20mg)
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: All patients, aged 18 years or older, who were scheduled to have primary unilateral THA/TKA for osteoarthritis (OA) or ANFH were considered eligible for included in the trial.
Exclusion criteria
Exclusion criteria: Patients with anemia (<120 g/L for female, <130 g/L for male), cardiovascular problems (history of myocardial infraction, angina, and atrial fibrillation), cerebrovascular conditions (history of previous stroke), thromboembolic disorders (history of deep-vein thrombosis (DVT) or pulmonary embolism (PE)), clotting disorders, known allergy to TXA
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| nflammatory index (CRP IL-6);fibrinolysis index (D-Dimer, FDP) ;coagulation indicator (PT, APTT, INR);TEG;antifactor Xa activity;total blood loss;Hidden blood loss;Hb drop; | — |
Secondary
| Measure | Time frame |
|---|---|
| transfusion;Range of motion;VAS score; | — |
Countries
China
Contacts
Public ContactFuxing Pei
West China Hospital, Sichuan University
Outcome results
None listed